Latex extracted from Hevea brasiliensis was used as an occlusive membrane for guided bone regeneration. Twenty-four rabbits were divided in two groups: treated and control group. Critical size bone defects (2 cm × 1 cm) were surgically made in the rabbit calvarium. Two latex membranes were implanted in each animal of the treated group, whereas the control defect was filled only with autogenous blood clot. After 15, 30, 60, and 120 days, animals from each group were euthanized, and the samples with regenerated bone were removed. No signs of allergy or rejection were noticed around the calvarial bone defect of the treated group. In the histological analysis, no foreign body inflammatory reaction was observed in the adjacent tissues in contact with the membranes demonstrating that latex can be used at injured sites as an aid in the healing process. Histological analysis, digital radiography, and electron spin resonance were used to evaluate the progress of bone repair. The results show significant differences between groups (p < 0.05) suggesting that latex membranes accelerates healing in critical bone defects.

In this work, we propose natural rubber latex (NRL) membranes as a protein delivery system. For this purpose Bovine Serum Albumin (BSA) was incorporated into the latex solution for in vitro protein delivery experiments. Different polymerization temperatures were used, from -10 to 27 °C, in order to control the membrane morphology. These membranes were characterized by Scanning Electron Microscopy (SEM), Atomic Force Microscopy (AFM), as well as the Lowry Method to measure the BSA release. SEM and AFM microscopy analysis showed that the number, size and distribution of pores in NRL membranes can be varied, as well as its overall morphology. We have found that the morphology of the membrane is the predominant factor for higher protein release, compared with pore size and number of pores. Results demonstrated that the best drug-delivery system was the membrane polymerized at RT (27 °C), which does release 66% of its BSA content for up to 18 days. Our results indicate that NRLb could be used in the future as an active membrane that could accelerate bone healing in GBR.

Natural Rubber Latex (NRL) can be used successfully in controlled release drug delivery due to their excellent matrix forming properties. Recently, NRL has shown to stimulate angiogenesis, cellular adhesion and the formation of extracellular matrix, promoting the replacement and regeneration of tissue. A dermatological delivery system comprising a topically acceptable, inert support impregnated with a metronidazole (MET) solution was developed. MET 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethanol, has been widely used for the treatment of protozoa and anaerobic bacterial infections. MET is a nitroimidazole anti-infective medication used mainly in the treatment of infections caused by susceptible organisms, particularly anaerobic bacteria and protozoa. In a previous study, we have tested NRL as an occlusive membrane for GBR with promising results. One possible way to decrease the inflammatory process, it was incorporated the MET in NRL. MET was incorporated into the NRL, by mixing it in solution for in vitro protein delivery experiments. The solutions of latex and MET were polymerized at different temperatures, from -100 to 40 °C, in order to control the membrane morphology. SEM microscopy analysis showed that the number, size and distribution of pores in NRL membranes varied depending on polymerization temperature, as well as its overall morphology. Results demonstrated that the best drug-delivery system was the membrane polymerized at -100 °C, which does release 77,1% of its MET content for up 310 hours.

A new low-level laser therapy (LLLT) protocol is proposed and compared to another previously studied, in animal models, aiming to establish a more practical LLLT protocol. Protocol 1, the same used in other works and based on the clinical LLLT protocol for bone regeneration, consists of punctual transcutaneous applications in the defect region with fluence of 16 J/cm(2) every 48 h for 15 days. Protocol 2, proposed in this work, consists of three sessions: the first application directly on the defect site with fluency of 3.7 J/cm(2), during the surgical procedure, followed by two transcutaneous applications, 48 and 120 h postoperatively. The Thera Lase® (λ = 830 nm) was used, and the dosimetry of the first application of protocol 2 was calculated based on in vitro studies. Forty-five male rats were used, in which critical-size bone defects with 8 mm of diameter were surgically created in calvaria. The animals were randomly divided into three groups of 15 animals, named group 1 (protocol 1), group 2 (protocol 2), and control, which was not submitted to laser treatment. After 7, 15, and 45 days, five animals of each group were euthanized, and the pieces of calvarial bone were collected for microscopic and immunohistochemistry for vascular endothelial growth factor (VEGF), osteocalcin (OC), and osteopontin (OP) analysis. Histomorphometry showed that newly formed bone of 15-day samples from group 2 is higher than the control group (p < 0.05, ANOVA, Tukey). At 7 days, in the central part of the defect, VEGF expression was the same for all groups, OC was higher for protocol 2, and OP for protocol 1. The results suggest LLLT using the protocol 2 hastened the bone healing process in the early periods after surgery.

No abstract